Drug discovery for leishmaniasis
β Gil, Carmen; Rivas, Luis
π Library
π
2018
π Royal Society of Chemistry
π English
β¦ LIBER β¦
π
Drug discovery for leishmaniasis
β Scribed by Luis Rivas, Luis Rivas, Carmen Gil, Carmen Gil, David Thurston, Ana Martinez, Philippe Desjeux, Jorge Alvar, Charles Mowdray, Fabiana Alves, Vanessa Yardley, Julio Martin, Christopher Fernandez, Nuria Campillo, Joao Henrique G Lago, Cynthia Demicheli, Katharine Carter, Miguel Angel Morales, Dan Zilberstein, Paul A Michels, Ana Tomas, Rafael BalaΓ±a, Louis Maes, Albert Descoteaux
- Publisher
- Royal Society of Chemistry
- Year
- 2018
- Tongue
- English
- Leaves
- 422
- Series
- Drug discovery series No. 60
- Edition
- 1
- Category
- Library
β¬ Acquire This Volume
No coin nor oath required. For personal study only.
β¦ Synopsis
For human health, leishmaniasis is among the most important protozoan diseases, superseded only by malaria. Globally, 10 to 12 million people are infected with 1.5 million new cases every year. The development of cheaper new drugs is urgently needed for this neglected disease that is developing resistance to current treatments. Chemotherapy remains the only treatment option for the bulk of patients. However, this is largely unaffordable for most. In the past three years numerous advances in drug discovery have been made for treating this disease by exploiting diverging metabolic pathways between the Leishmania enzymes and their hosts, using nanotechnology to target the immune cell phagolysosomes where Leishmania resides.
Drug Discovery for Leishmaniasis aims to provide a perspective of the current treatments and their challenges, blended with the emerging strategies and methodologies that will drive new target appraisals and drug developments, as well as addressing the molecular basis of resistance in Leishmania.
Recent studies have shown that leishmaniasis affects some of the poorest people in the world, with 95% of fatal cases occurring in only 6 countries. With the WHO goal of eliminating this public health problem in the South-east Asia Region by 2020, this book will be important for anyone who is interested in neglected tropical diseases.
β¦ Subjects
Leishmaniasis -- Treatment.;Drug development.;Leishmaniasis -- Chemotherapy.
π SIMILAR VOLUMES
Leishmania and Leishmaniasis
β Awanish Kumar (auth.)
π Library
π
2013
π Springer-Verlag New York
π English
<p>βLeishmania-related illnesses remain among the worldβs deadliest neglected tropical diseases, affecting approximately 12 million people in 88 countries. The mortality rate is substantial, contributing to nearly two million disability-adjusted life years. As more is understood about this parasite
Chemoinformatics for Drug Discovery
β JΓΌrgen Bajorath
π Library
π
2013
π Wiley
π English
<p><b>Chemoinformatics strategies to improve drug discovery results</b></p><p>With contributions from leading researchers in academia and the pharmaceutical industry as well as experts from the software industry, this book explains how chemoinformatics enhances drug discovery and pharmaceutical rese
Drug Discovery for Schizophrenia
β Tatiana V Lipina, Tatiana V Lipina, John C Roder, David Thurston, Ana Martinez,
π Library
π
2015
π Royal Society of Chemistry 44
π English
Since the pioneering pharmacotherapy for treatment of schizophrenia in the 1950s by antipsychotics, only a few major innovations have been made, pointing to a general stagnation in the field of pharmacology of schizophrenia. <STRONG>Drug Discovery for Schizophrenia</STRONG> covers new insights in th
Drug Discovery for Schizophrenia
β Tatiana V Lipina, Tatiana V Lipina, John C Roder, David Thurston, Ana Martinez,
π Library
π
2015
π Royal Society of Chemistry
π English
Since the pioneering pharmacotherapy for treatment of schizophrenia in the 1950s by antipsychotics, only a few major innovations have been made, pointing to a general stagnation in the field of pharmacology of schizophrenia. <STRONG>Drug Discovery for Schizophrenia</STRONG> covers new insights in th
Epigenetics for Drug Discovery
β Nessa Carey (ed.)
π Library
π
2015
π National Book Network International,Royal Society
π English
<P>Epigenetics is one of the fastest moving fields in drug discovery, with almost every large pharmaceutical company and a substantial number of biotechnology companies targeting epigenetic processes to treat diseases ranging from cancer to Huntingtonβs disease and from inflammation to sickle cell a